Pacific Biosciences of California Inc. logo

Pacific Biosciences of California Inc.

PACB | NASDAQ
Chart Builder DCF Calculator
$1.36
-$0.01 (-0.73%)
At close: Sep 21, 2026, 4:00 PM ET
$1.38
+$0.02 (+1.24%)
Pre-market: Sep 22, 2026, 4:21 AM ET

Company Profile

Pacific Biosciences of California, Inc. (PACB) specializes in pioneering and manufacturing advanced genetic sequencing platforms, empowering researchers and institutions to unravel intricate genetic challenges. At the heart of its offerings are the proprietary PacBio Sequencing Systems, designed for executing, monitoring, and interpreting biochemical sequencing reactions. Complementing these instruments are essential consumable products, such as their unique single molecule real-time (SMRT) cells. Furthermore, the company supplies a comprehensive suite of workflow-specific reagent kits. These include template preparation kits, which utilize molecular biology reagents (like ligase, buffers, and exonucleases) to convert DNA into SMRTbell double-stranded DNA libraries. Binding kits, featuring modified DNA polymerase, facilitate the crucial attachment of SMRTbell libraries to the polymerase in readiness for sequencing. Finally, specialized sequencing kits contain all necessary reagents, including phospholinked nucleotides, for real-time sequencing directly on their instruments. Pacific Biosciences caters to a broad global clientele, encompassing prominent research institutions, commercial diagnostic laboratories, large-scale genome centers, public health organizations, hospitals, clinical research institutes, contract research organizations (CROs), academic bodies, pharmaceutical firms, and agricultural enterprises. Product commercialization is managed through a direct sales force across North America and Europe, complemented by a robust network of distribution partners spanning Asia, the Middle East, Africa, and Latin America. A significant strategic alliance includes a development and commercialization agreement with Invitae Corporation. Originally incorporated in 2000 as Nanofluidics, Inc., the company adopted its current name, Pacific Biosciences of California, Inc., in 2005. Its corporate headquarters are situated in Menlo Park, California.

Key Executives

Name Position
Mark Van Oene President, Chief Executive Officer & Director
Natalie Welch Chief People Officer
Brett Atkins General Counsel & Corporate Secretary
Christian O. Henry Senior Business Advisor & Director
James R. Gibson CFO & Principal Accounting Officer
Stephen Turner Co-Founder

Latest SEC Filings

Date Type Title
Aug 18, 2026 4 Filing
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 11, 2026 4 Filing
Aug 07, 2026 S-8 Filing
Aug 06, 2026 10-Q Quarterly Report
Aug 05, 2026 8-K Current Report
Jul 09, 2026 8-K Current Report
Jun 04, 2026 4 Filing
Jun 04, 2026 4 Filing
Jun 04, 2026 4 Filing
View All SEC Filings
Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc. logo
Country United States
IPO Date Oct 26, 2010
Industry Medical - Devices
Sector Healthcare
Employees 485
CEO Mark Van Oene

Contact Details

1305 O’Brien Drive Menlo Park, California 94025 United States

Stock Details

Ticker Symbol PACB
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001299130
CUSIP Number 69404D108
ISIN Number US69404D1081
SIC Code 3826

© 2026 bestshares.com. All rights reserved.